Encephalitozoonosis: evidence for vertical transmission.

R. D. Hunt,N. King,Henry L. Foster

DOI: https://doi.org/10.1093/INFDIS/126.2.212

1972-08-01

Abstract:Encephalitozoonosis (nosematosis) caused by the microsporidium Encephalitozoon cuniculi (Nosema cuniculi) is an infectious disease that occurs frequently in laboratory rabbits and mice. The infection, which is usually latent or subclinical, is most often detected by the discovery of character

What problem does this paper attempt to address?

Rea regulates microglial polarization and attenuates neuronal apoptosis via inhibition of the NF-B and MAPK signalings for spinal cord injury repair

Shining Xiao,Chenggui Wang,Quanming Yang,Haibin Xu,Jinwei Lu,Kan Xu

DOI: https://doi.org/10.1111/jcmm.16220

2021-01-01

Journal of Cellular and Molecular Medicine

Abstract:Inflammation and neuronal apoptosis aggravate the secondary damage after spinal cord injury (SCI). Rehmannioside A (Rea) is a bioactive herbal extract isolated from Rehmanniae radix with low toxicity and neuroprotection effects. Rea treatment inhibited the release of pro-inflammatory mediators from microglial cells, and promoted M2 polarization in vitro, which in turn protected the co-cultured neurons from apoptosis via suppression of the NF-kappa B and MAPK signalling pathways. Furthermore, daily intraperitoneal injections of 80 mg/kg Rea into a rat model of SCI significantly improved the behavioural and histological indices, promoted M2 microglial polarization, alleviated neuronal apoptosis, and increased motor function recovery. Therefore, Rea is a promising therapeutic option for SCI and should be clinically explored.
Phosphodiesterase inhibitor modulation of brain microvascular endothelial cell barrier properties.

Shuo Liu,Chuanhui Yu,Fan Yang,Annlia Paganini-Hill,Mark J Fisher

DOI: https://doi.org/10.1016/j.jns.2012.06.005

IF: 4.4

2012-01-01

Journal of the Neurological Sciences

Abstract:Brain microvascular disorders, including cerebral microscopic hemorrhage, have high prevalence but few treatment options. To develop new strategies for these disorders, we analyzed the effects of several phosphodiesterase (PDE) inhibitors on human brain microvascular endothelial cells (HBECs).We modified barrier properties and response to histamine of HBECs using cilostazol (PDE3 inhibitor), rolipram (PDE4 inhibitor), and dipyridamole (non-specific PDE inhibitor).Cilostazol and dipyridamole altered the distribution of endothelial F-actin. Cilostazol increased expression of tight junction protein claudin-5 by 118% compared to control (p<.001). Permeability to albumin was decreased by cilostazol (21% vs control, p<.05), and permeability to dextran (70Kd) was decreased by both cilostazol (37% vs control, p<.001) and dipyridamole (44% vs control, p<.0001). Cilostazol increased trans-endothelial electrical resistance (TEER) after 12h by 111% compared to control (p<.0001). Protein kinase A (PKA) inhibitors H89 and KT5720 attenuated the TEER increase by cilostazol. Transient increased permeability in response to histamine was significantly mitigated by cilostazol, but not by other PDE inhibitors.These findings demonstrate distinctive effects of cilostazol and other PDE inhibitors on HBECs, including enhanced barrier characteristics and mitigation of response to histamine. PKA-mediated effects of cilostazol were prominent in this model. These in vitro findings are consistent with therapeutic potential of PDE inhibitors in human brain microvascular disorders.
Palmitoylethanolamide ameliorates neuroinflammation via modulating PPAR-α to promote the functional outcome after intracerebral hemorrhage

Guoyang Zhou,Xiongjie Fu,Liang Wang,Yang Cao,JianFeng Zhuang,Junwen Hu,Yin Li,Chaoran Xu,Shiqi Gao,Anwen Shao,Lin Wang

DOI: https://doi.org/10.1016/j.neulet.2022.136648

IF: 3.197

2022-06-01

Neuroscience Letters

Abstract:Intracerebral hemorrhage is a type of acute cerebrovascular disease that remains one of the main causes of death and disability. After the onset of ICH, different types of severe pathophysiological changes can cause great damage to brain tissue, including neuroinflammation. Our study demonstrated the effect of PEA on modulating microglia phenotype and neuroinflammation, as well as the possible underlying mechanisms after ICH for the first time. The phenotypic transformation of microglia and simulation of neuroinflammation after ICH in vitro was induced by hemoglobin on BV2 cells. Additionally, the experiment in vivo model was induced by collagenase injection in mice. The role of PEA on hematoma clearance was also discussed. Western blot, ELISA and immunofluorescence staining were used to determine the phenotypic polarization of microglia and neuroinflammation. In order to evaluate the role of PPAR-α in the anti-inflammatory effect of PEA after ICH, the PPAR-α antagonist GW6471 was utilized. Behavior tests examined the effect of PEA on improving neuronal function. Our results showed that PEA can ameliorate neuroinflammation by inhibiting upregulation of NF-κB, IL-1β and TNF-α, both in vivo and in vitro. Additionally, PEA can improve motor function in ICH mice and promotes hematoma clearance. At the same time, PEA can increase the levels of PPAR-α in the nucleus. Hence, PPAR-α antagonists can reverse the protective effects of PEA on neuroinflammation. These results suggest that PEA is involved in microglia polarization, attenuating the activation of neuroinflammation, as well as improving motor function after ICH. This, at least in part, may contribute to the involvement of PPAR-α modulation of NF-κB.

neurosciences
Oleoylethanolamide Protects against Acute Ischemic Stroke by Promoting PPARα-Mediated Microglia/Macrophage M2 Polarization

Ying Li,Yanan Zhang,Qing Wang,Chuang Wu,Guicheng Du,Lichao Yang

DOI: https://doi.org/10.3390/ph16040621

IF: 4.6

2023-04-21

Pharmaceuticals

Abstract:Oleoylethanolamide (OEA) has been demonstrated to be a feasible protectant in ischemic stroke. However, the mechanism for OEA-afforded neuroprotection remains elusive. The present study aimed to investigate the neuroprotective effects of OEA on peroxisome proliferator-activated receptor α (PPARα)-mediated microglia M2 polarization after cerebral ischemia. Transient middle cerebral artery occlusion (tMCAO) was induced for 1 h in wild-type (WT) or PPARα-knock-out (KO) mice. Mouse small glioma cells (BV2) microglia and primary microglia cultures were used to evaluate the direct effect of OEA on microglia. A coculture system was used to further elucidate the effect of OEA on microglial polarization and ischemic neurons' fate. OEA promoted the microglia switch from an inflammatory M1 phenotype to the protective M2 phenotype and enhanced the binding of PPARα with the arginase1 (Arg1) and Ym1 promoter in WT mice but not in KO mice after MCAO. Notably, the increased M2 microglia caused by OEA treatment were strongly linked to neuron survival after ischemic stroke. In vitro studies confirmed that OEA shifted BV2 microglia from (lipopolysaccharide) LPS-induced M1-like to M2-like phenotype through PPARα. Additionally, the activation of PPARα in primary microglia by OEA led to an M2 protective phenotype that enhanced neuronal survival against oxygen-glucose deprivation (OGD) in the coculture systems. Our findings demonstrate the novel effects of OEA in enhancing microglia M2 polarization to protect neighboring neurons by activating the PPARα signal, which is a new mechanism of OEA against cerebral ischemic injury. Therefore, OEA might be a promising therapeutic drug for stroke and targeting PPARα-mediated M2 microglia may represent a new strategy to treat ischemic stroke.

pharmacology & pharmacy,chemistry, medicinal
Palmitoylethanolamide Modulation of Microglia Activation: Characterization of Mechanisms of Action and Implication for Its Neuroprotective Effects

Alessia D’Aloia,Laura Molteni,Francesca Gullo,Elena Bresciani,Valentina Artusa,Laura Rizzi,Michela Ceriani,Ramona Meanti,Marzia Lecchi,Silvia Coco,Barbara Costa,Antonio Torsello

DOI: https://doi.org/10.3390/ijms22063054

IF: 5.6

2021-03-17

International Journal of Molecular Sciences

Abstract:Palmitoylethanolamide (PEA) is an endogenous lipid produced on demand by neurons and glial cells that displays neuroprotective properties. It is well known that inflammation and neuronal damage are strictly related processes and that microglia play a pivotal role in their regulation. The aim of the present work was to assess whether PEA could exert its neuroprotective and anti-inflammatory effects through the modulation of microglia reactive phenotypes. In N9 microglial cells, the pre-incubation with PEA blunted the increase of M1 pro-inflammatory markers induced by lipopolysaccharide (LPS), concomitantly increasing those M2 anti-inflammatory markers. Images of microglial cells were processed to obtain a set of morphological parameters that highlighted the ability of PEA to inhibit the LPS-induced M1 polarization and suggested that PEA might induce the anti-inflammatory M2a phenotype. Functionally, PEA prevented Ca2+ transients in both N9 cells and primary microglia and antagonized the neuronal hyperexcitability induced by LPS, as revealed by multi-electrode array (MEA) measurements on primary cortical cultures of neurons, microglia, and astrocyte. Finally, the investigation of the molecular pathway indicated that PEA effects are not mediated by toll-like receptor 4 (TLR4); on the contrary, a partial involvement of cannabinoid type 2 receptor (CB2R) was shown by using a selective receptor inverse agonist.

biochemistry & molecular biology,chemistry, multidisciplinary
Identification of a Novel Lipopolysaccharide-Inducible Gene with Key Features of Both a Kinase Anchor Proteins and chs1/beige Proteins1

Jia-Wang Wang,J. Howson,E. Haller,W. Kerr

DOI: https://doi.org/10.4049/jimmunol.166.7.4586

2001-04-01

Abstract:Mutations in chs1/beige result in a deficiency in intracellular transport of vesicles that leads to a generalized immunodeficiency in mice and humans. The function of NK cells, CTL, and granulocytes is impaired by these mutations, indicating that polarized trafficking of vesicles is controlled by CHS1/beige proteins. However, a molecular explanation for this defect has not been identified. Here we describe a novel gene with orthologues in mice, humans, and flies that contains key features of both chs1/beige and A kinase anchor genes. We designate this novel gene lba for LPS-responsive, beige-like anchor gene. Expression of lba is induced after LPS stimulation of B cells and macrophages. In addition, lba is expressed in many other tissues in the body and has three distinct mRNA isoforms that are differentially expressed in various tissues. Strikingly, LBA-green-fluorescent protein (GFP) fusion proteins are localized to vesicles after LPS stimulation. Confocal microscopy indicates this protein is colocalized with the trans-Golgi complex and some lysosomes. Further analysis by immunoelectron microscopy demonstrates that LBA-GFP fusion protein can localize to endoplasmic reticulum, plasma membrane, and endocytosis vesicles in addition to the trans-Golgi complex and lysosomes. We hypothesize that LBA/CHS1/BG proteins function in polarized vesicle trafficking by guiding intracellular vesicles to activated receptor complexes and thus facilitate polarized secretion and/or membrane deposition of immune effector molecules.
PPARα agonist relieves spinal cord injury in rats by activating Nrf2/HO-1 via the Raf-1/MEK/ERK pathway

Haocong Zhang,Dulei Xiang,Xinwei Liu,Liangbi Xiang

DOI: https://doi.org/10.18632/aging.203699

2021-11-19

Abstract:Objective: To observe the inhibitory effects of the peroxisome proliferator-activated receptor alpha (PPARα) agonist palmitoylethanolamide (PEA) on inflammatory responses and oxidative stress injury in rats with spinal cord injury (SCI). Methods: The SCI rat model was established using modified Allen's method and the changes in rats' joint motion were observed by Basso, Beattie and Bresnahan locomotor rating scale (BBB scale) at 1, 3 and 7 days after modeling, HE Staining and Nissl Staining has been carried out to evaluate the pathological lesion of spinal cords in rats. Besides, Immunohistochemical (IHC) was performed to detect the reactive oxygen species (ROS), expression levels of acrylamide (ACR) and manganese superoxide dismutase (MnSOD) in rat spinal cords, and Western Blotting was applied to measure protein expression levels of nuclear factor-kappa B (NF-κB), B cell lymphoma-2 (Bcl-2), BCL-2 associated X (BAX), phosphoinositide 3-kinase (PI3K), protein kinase B (Akt), phosphorylated (p)-Akt, HO-1, Nrf2, trithorax-1 (TRX-1), Raf-1, MEK, ERK, p-MEK and p-ERK. Results: The PPARα agonist PEA could alleviate SCI in rats, inhibit inflammatory responses, mitigate oxidative stress injury, reduce the apoptotic rate and promote SCI rats motor function recovery. In addition, the PPARα agonist PEA was able to activate the phosphorylation of MEK and ERK, stimulate Nrf-2 translocation into the nucleus and up-regulate the expressions of HO-1 and TRX-1. Conclusion: PPARα agonist PEA can relieve SCI in rats by inhibiting inflammatory responses and oxidative stress, which may involve a mechanism associated with the activation of Nrf2/HO-1 via the Raf-1/MEK/ERK pathway.
Palmitoylethanolamide causes dose-dependent changes in brain function and the lipidome

Shreyas Balaji,Taylor J. Woodward,Emily Richter,Arnold Chang,Richard Otiz,Praveen P. Kulkarni,Kaashyap Balaji,Heather B. Bradshaw,Craig F. Ferris

DOI: https://doi.org/10.3389/fnins.2024.1506352

IF: 4.3

2024-11-28

Frontiers in Neuroscience

Abstract:The present studies were undertaken to understand the effects of the commonly used nutraceutical PEA on brain function and lipid chemistry. These studies using MRI and broad-scale lipidomics are without precedent in animal or human research. During the MRI scanning session awake rats were given one of three doses of PEA (3, 10, or 30 mg/kg) or vehicle and imaged for changes in BOLD signal and functional connectivity. There was an inverse dose–response for negative BOLD suggesting a decrease in brain activity affecting the prefrontal ctx, sensorimotor cortices, basal ganglia and thalamus. However, there was a dose-dependent increase in functional connectivity in these same brain areas. Plasma and CNS levels of PEA and over 80 endogenous lipids (endolipids) were determined post treatment. While levels of PEA in the CNS were significantly higher after 30 mg/kg treatment, levels of the endocannabinoid, Anandamide, and at least 20 additional endolipids, were significantly lower across the CNS. Of the 78 endolipids that were detected in all CNS regions evaluated, 51 of them were modulated in at least one of the regions. Taken together, the functional connectivity and lipidomics changes provide evidence that PEA treatment drives substantial changes in CNS activity.

neurosciences
Protective Effects of Ultramicronized Palmitoylethanolamide (PEA-um) in Myocardial Ischaemia and Reperfusion Injury in VIVO

Rosanna Di Paola,Marika Cordaro,Rosalia Crupi,Rosalba Siracusa,Michela Campolo,Giuseppe Bruschetta,Roberta Fusco,Pietro Pugliatti,Emanuela Esposito,Salvatore Cuzzocrea

DOI: https://doi.org/10.1097/shk.0000000000000578

2016-08-01

Shock

Abstract:Myocardial infarction is the leading cause of death, occurs after prolonged ischemia of the coronary arteries. Restore blood flow is the first intervention help against heart attack. However, reperfusion of the arteries leads to ischemia/reperfusion injury (I/R). The fatty acid amide palmitoylethanolamide (PEA) is an endogenous compound widely present in living organisms, with analgesic and anti-inflammatory properties. The present study evaluated the effect of ultramicronized palmitoylethanolamide (PEA-um) treatment on the inflammatory process associated with myocardial I/R. Myocardial ischemia reperfusion injury was induced by occlusion of the left anterior descending coronary artery for 30 min followed by 2 h of reperfusion. PEA-um, was administered (10 mg/kg) 15 min after ischemia and 1 h after reperfusion. In this study, we demonstrated that PEA-um treatment reduces myocardial tissue injury, neutrophil infiltration, adhesion molecules (ICAM-1, P-selectin) expression, proinflammatory cytokines (TNF-α, IL-1β) production, nitrotyrosine and PAR formation, nuclear factor kB expression, and apoptosis (Fas-L, Bcl-2) activation. In addition to study whether the protective effect of PEA-um on myocardial ischemia reperfusion injury is also related to the activation of PPAR-α, in a separate set of experiments it has been performed myocardial I/R in PPARα mice. Genetic ablation of peroxisome proliferator activated receptor (PPAR)-α in PPAR-αKO mice exacerbated Myocardial ischemia reperfusion injury when compared with PPAR-αWT mice. PEA-um induced cardioprotection in PPAR-α wild-type mice, but the same effect cannot be observed in PPAR-αKO mice. Our results have clearly shown a modulation of the inflammatory process, associated with myocardial ischemia reperfusion injury, following administration of PEA-um.

surgery,peripheral vascular disease,hematology,critical care medicine
High-field electron transport in quantum wires studied by solution of the Boltzmann equation.

Yamada,Sone

DOI: https://doi.org/10.1103/PHYSREVB.40.6265

1989-09-15

Abstract:Les proprietes du transport d'electrons a champ eleve dans un fil quantique unidimensionnel de GaAs, sont etudiees par une nouvelle methode pour resoudre numeriquement l'equation de Boltzmann avec la statistique de Fermi-Dirac. Le fil est si etroit que des sous-bandes quantiques se forment. Dans ce modele on considere la diffusion des impuretes, des phonons optiques, et la diffusion inter-sous-bande
Effect of melengestrol acetate on synchronization of estrus, subsequent fertility and milk constituents of lactating dairy cows.

J. Roussel,J. F. Beatty

DOI: https://doi.org/10.3168/JDS.S0022-0302(69)86889-X

IF: 4.225

1969-12-01

Journal of Dairy Science

Abstract:Abstract The oral effectiveness of melengestrol acetate in estrus synchronization and its effect on milk yield and milk constituents was determined in 40 lactating dairy cows. Melengestrol acetate was fed at a rate of 1.0 mg/head/day for 14 consecutive days in 0.91 kg of a grain diet. It was observed that melengestrol acetate did not significantly affect milk yield, milk fat, solids-not-fat, or lactose level. Cows were not observed in standing estrus during the feeding period of melengestrol acetate. The occurrence of estrus after withdrawal was 93%. The mean interval from melengestrol acetate withdrawal to onset of the first and second post-treatment estrus was 4.9 and 21.9 days, respectively. The over-all conception rate (first and second service) for the control group was 53%, as compared to 60% for the melengestrol acetate group. Estrus synchronization in the hot summer months tends to have a slight adverse effect on the occurrence of post-melengestrol acetate estrus and on fertility, when compared to estrus synchronization during the cool seasons of the year.
Echinocystic Acid, a Natural Plant Extract, Alleviates Cerebral Ischemia/reperfusion Injury Via Inhibiting the JNK Signaling Pathway

Hailong Yu,Wei Li,Xiang Cao,Xinyue Wang,Yuanyuan Zhao,Lilong Song,Jian Chen,Sushan Wang,Beilei Chen,Yun Xu

DOI: https://doi.org/10.1016/j.ejphar.2019.172610

IF: 5.195

2019-01-01

European Journal of Pharmacology

Abstract:Echinocystic acid (EA) was found to possess antiviral, anti-inflammatory and antioxidation activities. A recent study showed the antiapoptotic effects of EA on acute myocardial infarction. In this study, we demonstrated the potential neuroprotective effects of EA on cerebral ischemia/reperfusion (I/R) injury in mice. Intraperitoneal injection of EA 1 h before ischemia significantly reduced the cerebral infarct volume and neurological deficit after 60 min of ischemia and 24 h of reperfusion. The neuroprotective effects of EA occurred in a dose-dependent manner. Then, we explored the mechanisms of neuroprotection by EA. This compound exerted antiapoptotic activity by upregulating the level of Bcl-2 and simultaneously downregulating the levels of cleaved caspase-3 and Bax. Furthermore, EA also possessed anti-inflammatory activity and prevented the excessive phosphorylation of NF-κB (p-P65) and the increase in IL-1β and IL-6 levels. Finally, our data indicated that EA treatment decreased the level of phosphorylated JNK in vivo, and the JNK activator anisomycin (AN) reversed the neuroprotective effects of EA, indicating that the JNK pathway is involved in the antiapoptotic and anti-inflammatory mechanisms of EA. In summary, our findings suggest that EA provides neuroprotective effects through its antiapoptotic and anti-inflammatory activities by inhibiting the JNK signaling pathway in cerebral I/R injury. Due to its safety and lack of toxicity, EA is a potential candidate for the treatment of ischemic stroke in future clinical trials.
Role of Rho Kinase in Lysophosphatidic Acid-Induced Altering of Blood-Brain Barrier Permeability.

Ying Yu,Jun Qin,Meizhen Liu,Qingyuan Ruan,Yiliang Li,Zhaohui Zhang

DOI: https://doi.org/10.3892/ijmm.2014.1618

IF: 5.314

2014-01-01

International Journal of Molecular Medicine

Abstract:Lysophosphatidic acid (LPA) the simplest of the water-soluble phospholipids, is produced by activated platelets, macrophage and endothelial cells. It also evokes various biological responses. When LPA concentrations reach high levels, brain injury, including stroke and intracerebral hemorrhage (ICH), occurs. Previous studies have shown that LPA is crucial in increasing blood-brain barrier (BBB) permeability, and the Rho/Rho kinase (ROCK) signaling pathway is involved in the regulation of endothelial permeability. However, the exact mechanism by which the Rho/ROCK pathway mediates BBB disruption induced by LPA remains to be determined. In the present study, we observed that LPA induced the increase of BBB permeability in the right striatum after 10 µl LPA (100 µM) was injected into the ipsilateral caudate nucleus of rats. The ROCK was involved in the expression of proteolytic enzymes, matrix metalloproteinase (MMP)-9 and urokinase-type plasminogen activator (uPA), leading to LPA-induced BBB disruption. ROCK inhibitor (Y27632) markedly inhibited the expression of proteolytic enzymes induced by LPA as well as the BBB disruption after it was co-injected with LPA. Thus, results of the present study suggest that LPA increases BBB permeability, which may be due to the Rho/ROCK signaling pathway and the subsequent production of proteolytic enzymes MMP-9 and uPA.
Phosphatidylethanolamine-Binding Protein 1 Ameliorates Ischemia-Induced Inflammation and Neuronal Damage in the Rabbit Spinal Cord

Woosuk Kim,Su Bin Cho,Hyo Young Jung,Dae Young Yoo,Jae Keun Oh,Goang-Min Choi,Tack-Geun Cho,Dae Won Kim,In Koo Hwang,Soo Young Choi,Seung Myung Moon,Kim,Cho,Jung,Yoo,Oh,Choi,Cho,Kim,Hwang,Choi,Moon

DOI: https://doi.org/10.3390/cells8111370

IF: 6

2019-10-31

Cells

Abstract:In a previous study, we utilized a proteomic approach and found a significant reduction in phosphatidylethanolamine-binding protein 1 (PEBP1) protein level in the spinal cord at 3 h after ischemia. In the present study, we investigated the role of PEBP1 against oxidative stress in NSC34 cells in vitro, and ischemic damage in the rabbit spinal cord in vivo. We generated a PEP-1-PEBP1 fusion protein to facilitate the penetration of blood-brain barrier and intracellular delivery of PEBP1 protein. Treatment with PEP-1-PEBP1 significantly decreased cell death and the induction of oxidative stress in NSC34 cells. Furthermore, administering PEP-1-PEBP1 did not show any significant side effects immediately before and after ischemia/reperfusion. Administration of PEP-PEBP1 improved the Tarlov’s neurological score at 24 and 72 h after ischemia, and significantly improved neuronal survival at 72 h after ischemia based on neuronal nuclei (NeuN) immunohistochemistry, Flouro-Jade B staining, and western blot study for cleaved caspase 3. PEP-1-PEBP1 administration decreased oxidative stress based on malondialdehyde level, advanced oxidation protein products, and 8-iso-prostaglandin F2α in the spinal cord. In addition, inflammation based on myeloperoxidase level, tumor necrosis factor-α level, and high mobility group box 1 level was decreased by PEP-1-PEBP1 treatment at 72 h after ischemia. Thus, PEP-1-PEBP1 treatment, which decreases oxidative stress, inflammatory cytokines, and neuronal death, may be an effective therapeutic strategy for spinal cord ischemia.

cell biology
Neuroprotective Effects of Prostaglandin A(1) in Rat Models of Permanent Focal Cerebral Ischemia Are Associated with Nuclear Factor-Kappa B Inhibition and Peroxisome Proliferator-Activated Receptor-Gamma Up-Regulation

Hui-Ling Zhang,Zhen-Lun Gu,Sean I. Savitz,Feng Han,Kohji Fukunaga,Zheng-Hong Qin

DOI: https://doi.org/10.1002/jnr.21569

IF: 4.433

2007-01-01

Journal of Neuroscience Research

Abstract:We have previously reported that prostaglandin A(1) (PGA(1)) reduces infarct size in rodent models of focal ischemia. This study seeks to elucidate the possible molecular mechanisms underlying PGA(1)'s neuroprotective effects against ischemic injury. Rats were subjected to permanent middle cerebral artery occlusion (pMCAO) by intraluminal suture blockade. PGA(1) was injected intracerebroventricularly (icv) immediately after ischemic onset. Western blot analysis was employed to determine alterations in IkappaBalpha, pIKKalpha, and peroxisome proliferator-activated receptor-gamma (PPAR-gamma). Immunohistochemistry was used to confirm the nuclear translocation of nuclear factor-kappaB (NF-kappaB) p65 and the expression of PPAR-gamma. RT-PCR was used to detect levels of c-Myc mRNA. The contribution of PPAR-gamma to PGA(1)'s neuroprotection was evaluated by pretreatment with the PPAR-gamma irreversible antagonist GW9662. A brief increase in pIKKalpha levels and rapid reduction in IkappaBalpha were observed after ischemia. PGA(1) blocked ischemia-induced increases in pIKKalpha levels and reversed the decline in IkappaBalpha levels. Ischemia-induced nuclear translocation of NF-kappaB p65 was attenuated by PGA(1). PGA(1) also repressed the ischemia-induced increase in expression of NF-kappaB target gene c-Myc mRNA. Immunohistochemistry demonstrated an increase in PPAR-gamma immunoreactivity in the nucleus of striatal cells at 3 hr after pMCAO. Western blot analysis revealed that the expression of PPAR-gamma protein significantly increased at 12 hr and peaked at 24 hr. PGA(1) enhanced the ischemia-triggered induction of PPAR-gamma protein. Pretreatment with the irreversible PPAR-gamma antagonist GW9662 attenuated PGA(1)'s neuroprotection against ischemia. These findings suggest that PGA(1)-mediated neuroprotective effect against ischemia appears to be associated with blocking NF-kappaB activation and likely with up-regulating PPAR-gamma expression.
N-Palmitoylethanolamine-oxazoline (PEA-OXA): A new therapeutic strategy to reduce neuroinflammation, oxidative stress associated to vascular dementia in an experimental model of repeated bilateral common carotid arteries occlusion

Daniela Impellizzeri,Rosalba Siracusa,Marika Cordaro,Rosalia Crupi,Alessio Filippo Peritore,Enrico Gugliandolo,Ramona D'Amico,Stefania Petrosino,Maurizio Evangelista,Rosanna Di Paola,Salvatore Cuzzocrea

DOI: https://doi.org/10.1016/j.nbd.2019.01.007

IF: 7.046

2019-05-01

Neurobiology of Disease

Abstract:AIM: Recent studies revealed that pharmacological modulation of NAE-hydrolyzing acid amidase (NAAA) can be achieved with PEA oxazoline (PEA-OXA). Hence, the aim of the present work was to thoroughly evaluate the anti-inflammatory and neuroprotective effects of PEA-OXA in an experimental model of vascular dementia (VaD) induced by bilateral carotid arteries occlusion. At 24 h after VaD induction, animals were orally administered with 10 mg/kg of PEA-OXA daily for 15 days.RESULTS: Brain tissues were handled for histological, immunohistochemical, western blot, and immunofluorescence analysis. PEA-OXA treatment evidently reduced the histological alterations and neuronal death induced by VaD and additionally improved behavioral deficits. Further, PEA-OXA decreased GFAP and Iba-1, markers of astrocytes, and microglia activation, as well as increased MAP-2, a marker of neuron development. Moreover, PEA-OXA reduced oxidative stress, modulated Nrf2-mediated antioxidant response, and inhibited the apoptotic process.INNOVATION: Some drugs may demonstrate their healing potential by regulating neuroinflammation, rather than by their habitually attributed actions only. Palmitoylethanolamide (PEA) is a prototype ALIAmide, well-known for its analgesic, anti-inflammatory, and neuroprotective properties. The inhibition of PEA degradation by targeting NAAA, its catabolic enzyme, is a different approach for treating neuroinflammation. This research offers new insight into the mechanism of PEA-OXA-induced neuroprotection.CONCLUSION: Thus, the modulation of intracellular NAAA by PEA-OXA could offer a novel means of controlling neuroinflammatory conditions associated with VaD.

neurosciences
Neuroprotective effects of phenylacetylglycine via β2AR on cerebral ischemia/reperfusion injury in rats

Wenjie Hu,Xueyan Kuang,Yao Zhang,Yimin Luo,Litao Zhang

DOI: https://doi.org/10.1016/j.jsps.2024.102210

IF: 4.562

2024-11-29

Saudi Pharmaceutical Journal

Abstract:Phenylacetylglycine (PAGly) is a small molecule derived from phenylalanine in the gut via glycine degradation and conjugation. It has been associated with both the progression of atherosclerosis and protective effects on the myocardium. This study evaluated the function and the underlying mechanisms of PAGly in a rat cerebral ischemia/reperfusion (I/R) injury model. The results indicated that PAGly markedly alleviated cerebral infarct volume ( P = 0.0024) and improved the neurobehavioral outcomes ( P = 0.0149) after I/R injury. PAGly is structurally analogous to catecholamines and binds to β2-adrenergic receptors (β2AR) on microglia without altering the expression of these receptors ( P = 0.9137), but instead inhibiting their activity. It was also observed that when β2AR was engaged in microglia, PAGly suppressed the release of TNF-α ( P = 0.0018), IL-1β ( P = 0.0310), and IL-6 ( P = 0.0017), thereby reducing neuronal apoptosis ( P = 0.000003). Furthermore, the protective effect of PAGly diminished after the administration of β2AR-specific agonist fenoterol ( P = 0.0055). These data indicate that PAGly mitigates cerebral I/R injury by inhibiting microglial inflammation via β2AR, highlighting its potential as a therapeutic agent. These findings position PAGly as a promising candidate for therapeutic intervention in cerebrovascular injuries, warranting further exploration in clinical settings.

pharmacology & pharmacy
The Aldose Reductase Inhibitor Epalrestat Maintains Blood–Brain Barrier Integrity by Enhancing Endothelial Cell Function during Cerebral Ischemia

Tongshuai Zhang,Jinrong Wu,Xinmin Yao,Yao Zhang,Yue Wang,Yang Han,Yun Wu,Zhenyu Xu,Jing Lan,Siyu Han,Haifeng Zou,Qixu Sun,Dandan Wang,Jingyu Zhang,Guangyou Wang

DOI: https://doi.org/10.1007/s12035-023-03304-z

IF: 5.682

2023-03-20

Molecular Neurobiology

Abstract:Abstract Excessive activation of aldose reductase (AR) in the brain is a risk factor for aggravating cerebral ischemia injury. Epalrestat is the only AR inhibitor with proven safety and efficacy, which is used in the clinical treatment of diabetic neuropathy. However, the molecular mechanisms underlying the neuroprotection of epalrestat remain unknown in the ischemic brain. Recent studies have found that blood–brain barrier (BBB) damage was mainly caused by increased apoptosis and autophagy of brain microvascular endothelial cells (BMVECs) and decreased expression of tight junction proteins. Thus, we hypothesized that the protective effect of epalrestat is mainly related to regulating the survival of BMVECs and tight junction protein levels after cerebral ischemia. To test this hypothesis, a mouse model of cerebral ischemia was established by permanent middle cerebral artery ligation (pMCAL), and the mice were treated with epalrestat or saline as a control. Epalrestat reduced the ischemic volume, enhanced BBB function, and improved the neurobehavior after cerebral ischemia. In vitro studies revealed that epalrestat increased the expression of tight junction proteins, and reduced the levels of cleaved-caspase3 and LC3 proteins in mouse BMVECs (bEnd.3 cells) exposed to oxygen–glucose deprivation (OGD). In addition, bicalutamide (an AKT inhibitor) and rapamycin (an mTOR inhibitor) increased the epalrestat-induced reduction in apoptosis and autophagy related protein levels in bEnd.3 cells with OGD treatment. Our findings suggest that epalrestat improves BBB function, which may be accomplished by reducing AR activation, promoting tight junction proteins expression, and upregulating AKT/mTOR signaling pathway to inhibit apoptosis and autophagy in BMVECs.

neurosciences
Edaravone dexborneol protects against cerebral ischemia/reperfusion-induced blood-brain barrier damage by inhibiting ferroptosis via activation of nrf-2/HO-1/GPX4 signaling

Peng Xiao,Haiyan Huang,Hanshu Zhao,Ruijia Liu,Zhiyu Sun,Yushuang Liu,Nan Chen,Zhongling Zhang

DOI: https://doi.org/10.1016/j.freeradbiomed.2024.03.019

IF: 8.101

2024-03-28

Free Radical Biology and Medicine

Abstract:Purpose Ferroptosis has recently been recognized as a mechanism of cerebral ischemia-reperfusion (I/R) injury, attributed to blood-brain barrier (BBB) disruption. Edaravone dexboneol (Eda.B) is a novel neuroprotective agent widely employed in ischemic stroke, which is composed of edaravone (Eda) and dexborneol. This study aimed to investigate the protective effects of Eda.B on the BBB in cerebral I/R and explore its potential mechanisms. Methods Transient middle cerebral artery occlusion (tMCAO) Sprague-Dawley-rats model was used. Rats were randomly assigned to sham-operated group (sham, n = 20), model group (tMCAO, n = 20), Eda.B group (Eda.B, n = 20), Eda group (Eda, n = 20) and dexborneol group (dexborneol, n = 20), and Eda.B + Zinc protoporphyria group (Eda.B + ZnPP, n = 5). Infarct area, cellular apoptosis and neurofunctional recovery were accessed through TTC staining, TUNEL staining, and modified Garcia scoring system, respectively. BBB integrity was evaluated via Evans blue staining. Nuclear factor E2 related factor 2 (Nrf-2)/heme oxygenase 1 (HO-1)/glutathione peroxidase 4 (GPX4) signaling were qualified by Western blot. Transmission electron microscopy (TEM) revealed alterations in ipsilateral brain tissue among groups. Glutathione (GSH) and malondialdehyde (MDA) levels, and Fe 2+ tissue content determination were detected. Results Eda.B effectively improved neurological deficits, diminished infarct area and cellular apoptosis, as well as ameliorated BBB integrity in tMCAO rats. Further, Eda.B significantly inhibited ferroptosis, as evidenced by ameliorated pathological features of mitochondria, down-regulated of MDA and Fe 2+ levels and up-regulated GSH content. Mechanistically, Eda.B attenuated BBB disruption via Nrf-2-mediated ferroptosis, promoting nuclear translocation of Nrf-2, increasing HO-1, GPX4 expression, alleviating the loss of zonula occludens 1 (ZO-1) and occludin as well as decreasing 4-hydroxynonenal (4-HNE) level. Conclusions This study revealed for the first time that Eda.B safeguarded the BBB from cerebral I/R injury by inhibiting ferroptosis through the activation of the Nrf-2/HO-1/GPX4 axis, providing a novel insight into the neuroprotective effect of Eda.B in cerebral I/R.

biochemistry & molecular biology,endocrinology & metabolism
Oleoylethanolamide Ameliorates Motor Dysfunction Through PPARa-mediates Oligodendrocyte Differentiation and White Matter Integrity after Ischemic Stroke

Rengong Zhuo,Zhengmao Song,Yun Wang,Maoshu Zhu,Feng Liu,Pingli Lin,Rong Rao,Yu Zhou,Yun Zhao,Zhongxiong Fan,Lishan Cui,Hongtao Liu,Jingwen Li,Ying Li,Han Guo,Cheng Fu Cai,Lichao Yang

DOI: https://doi.org/10.1002/ptr.7970

2023-01-01

Abstract:Background and Aim: Our previous study has revealed that OEA promotes motor function recovery in the chronic stage of ischemic stroke. However, the neuroprotective mechanism of OEA on motor function recovery after stroke still is unexplored. Therefore, the aim of this study was to explore the effects of OEA treatment on angiogenesis, neurogenesis, and white matter repair in the peri-infarct region after cerebral ischemia. Experimental Procedure: The adult male rats were subjected to 2 h of middle cerebral artery occlusion. The rats were treated with 10 and 30 mg/kg OEA or vehicle daily starting from day 2 after ischemia induction until they were sacrificed. Key Results and Conclusions: The results revealed that OEA increased cortical angiogenesis, neural progenitor cells (NPCs) proliferation, migration, and differentiation. OEA treatment enhanced the survival of newborn neurons and oligodendrogenesis, which eventually repaired the cortical neuronal injury and improved motor function after ischemic stroke. Meanwhile, OEA treatment promoted the differentiation of oligodendrocyte progenitor cells (OPCs) and oligodendrogenesis by activating the PPARa signaling pathway. Our results showed that OEA restores motor function by facilitating cortical angiogenesis, neurogenesis, and white matter repair in rats after ischemic stroke. Therefore, we demonstrate that OEA facilitates functional recovery after ischemic stroke and propose the hypothesis that the long-term application of OEA mitigates the disability after stroke.

Encephalitozoonosis: evidence for vertical transmission.

Rea regulates microglial polarization and attenuates neuronal apoptosis via inhibition of the NF-B and MAPK signalings for spinal cord injury repair

Phosphodiesterase inhibitor modulation of brain microvascular endothelial cell barrier properties.

Palmitoylethanolamide ameliorates neuroinflammation via modulating PPAR-α to promote the functional outcome after intracerebral hemorrhage

Oleoylethanolamide Protects against Acute Ischemic Stroke by Promoting PPARα-Mediated Microglia/Macrophage M2 Polarization

Palmitoylethanolamide Modulation of Microglia Activation: Characterization of Mechanisms of Action and Implication for Its Neuroprotective Effects

Identification of a Novel Lipopolysaccharide-Inducible Gene with Key Features of Both a Kinase Anchor Proteins and chs1/beige Proteins1

PPARα agonist relieves spinal cord injury in rats by activating Nrf2/HO-1 via the Raf-1/MEK/ERK pathway

Palmitoylethanolamide causes dose-dependent changes in brain function and the lipidome

Protective Effects of Ultramicronized Palmitoylethanolamide (PEA-um) in Myocardial Ischaemia and Reperfusion Injury in VIVO

High-field electron transport in quantum wires studied by solution of the Boltzmann equation.

Effect of melengestrol acetate on synchronization of estrus, subsequent fertility and milk constituents of lactating dairy cows.

Echinocystic Acid, a Natural Plant Extract, Alleviates Cerebral Ischemia/reperfusion Injury Via Inhibiting the JNK Signaling Pathway

Role of Rho Kinase in Lysophosphatidic Acid-Induced Altering of Blood-Brain Barrier Permeability.

Phosphatidylethanolamine-Binding Protein 1 Ameliorates Ischemia-Induced Inflammation and Neuronal Damage in the Rabbit Spinal Cord

Neuroprotective Effects of Prostaglandin A(1) in Rat Models of Permanent Focal Cerebral Ischemia Are Associated with Nuclear Factor-Kappa B Inhibition and Peroxisome Proliferator-Activated Receptor-Gamma Up-Regulation

N-Palmitoylethanolamine-oxazoline (PEA-OXA): A new therapeutic strategy to reduce neuroinflammation, oxidative stress associated to vascular dementia in an experimental model of repeated bilateral common carotid arteries occlusion

Neuroprotective effects of phenylacetylglycine via β2AR on cerebral ischemia/reperfusion injury in rats

The Aldose Reductase Inhibitor Epalrestat Maintains Blood–Brain Barrier Integrity by Enhancing Endothelial Cell Function during Cerebral Ischemia

Edaravone dexborneol protects against cerebral ischemia/reperfusion-induced blood-brain barrier damage by inhibiting ferroptosis via activation of nrf-2/HO-1/GPX4 signaling

Oleoylethanolamide Ameliorates Motor Dysfunction Through PPARa-mediates Oligodendrocyte Differentiation and White Matter Integrity after Ischemic Stroke